394 related articles for article (PubMed ID: 25964345)
1. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.
Shroff EH; Eberlin LS; Dang VM; Gouw AM; Gabay M; Adam SJ; Bellovin DI; Tran PT; Philbrick WM; Garcia-Ocana A; Casey SC; Li Y; Dang CV; Zare RN; Felsher DW
Proc Natl Acad Sci U S A; 2015 May; 112(21):6539-44. PubMed ID: 25964345
[TBL] [Abstract][Full Text] [Related]
2. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
[TBL] [Abstract][Full Text] [Related]
3. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.
Xiang Y; Stine ZE; Xia J; Lu Y; O'Connor RS; Altman BJ; Hsieh AL; Gouw AM; Thomas AG; Gao P; Sun L; Song L; Yan B; Slusher BS; Zhuo J; Ooi LL; Lee CG; Mancuso A; McCallion AS; Le A; Milone MC; Rayport S; Felsher DW; Dang CV
J Clin Invest; 2015 Jun; 125(6):2293-306. PubMed ID: 25915584
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
6. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development.
Xiao ZD; Han L; Lee H; Zhuang L; Zhang Y; Baddour J; Nagrath D; Wood CG; Gu J; Wu X; Liang H; Gan B
Nat Commun; 2017 Oct; 8(1):783. PubMed ID: 28978906
[TBL] [Abstract][Full Text] [Related]
7. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
[TBL] [Abstract][Full Text] [Related]
8. TRPM7 Regulates AKT/FOXO1-Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma.
Zhao Z; Zhang M; Duan X; Chen Y; Li E; Luo L; Wu W; Peng Z; Qiu H; Zeng G
Mol Cancer Res; 2018 Jun; 16(6):1013-1023. PubMed ID: 29545479
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of c-myc, c-fos and Harvey ras oncogenes in renal cancers--analysis at the messenger RNA levels].
Kunimi K; Uchibayashi T; Hisazumi H
Nihon Hinyokika Gakkai Zasshi; 1991 Dec; 82(12):1924-9. PubMed ID: 1779495
[TBL] [Abstract][Full Text] [Related]
10. c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.
Huang J; Kong W; Zhang J; Chen Y; Xue W; Liu D; Huang Y
Int J Oncol; 2016 Oct; 49(4):1569-75. PubMed ID: 27431728
[TBL] [Abstract][Full Text] [Related]
11. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.
Sejima T; Isoyama T; Miyagawa I
Int J Urol; 2003 Sep; 10(9):476-84. PubMed ID: 12941126
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
13. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
[TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.
Zhao Q; Kun D; Hong B; Deng X; Guo S; Tang X; Yang Y; Gong K; Li Q; Ye L; Jiang WG; Zhang N
Anticancer Res; 2017 Aug; 37(8):4379-4388. PubMed ID: 28739731
[TBL] [Abstract][Full Text] [Related]
16. Metabolic vulnerabilities of MYC-induced cancer.
Gouw AM; Toal GG; Felsher DW
Oncotarget; 2016 May; 7(21):29879-80. PubMed ID: 26863454
[No Abstract] [Full Text] [Related]
17. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
18. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
[TBL] [Abstract][Full Text] [Related]
20. MiR-199a targeting ROCK1 to affect kidney cell proliferation, invasion and apoptosis.
Qin Z; Wei X; Jin N; Wang Y; Zhao R; Hu Y; Yan W; Li J; Zhou Q
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1920-1925. PubMed ID: 29130345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
